bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA Read more about bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA
bluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol Read more about bluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol
Celgene and bluebird bio to Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA Read more about Celgene and bluebird bio to Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA
bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy Read more about bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
bluebird bio Announces Participation at the Jefferies 2015 Global Healthcare Conference Read more about bluebird bio Announces Participation at the Jefferies 2015 Global Healthcare Conference
bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association Read more about bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association
bluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major Read more about bluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major
bluebird bio Reports First Quarter 2015 Financial Results and Business Updates Read more about bluebird bio Reports First Quarter 2015 Financial Results and Business Updates
bluebird bio Announces Participation at Two Upcoming Health Care Conferences Read more about bluebird bio Announces Participation at Two Upcoming Health Care Conferences
bluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day Read more about bluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day